// App-Quantinova.ai

2407 : Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies

Researchers

Presenter

  • Fan Yang

Principal Investigators

  • Zhihui Li

  • Changwei Dong

  • Yang LEI

  • YanPing Geng

  • XiaoPei Wen

  • Yan Zhou

  • Tong Wu

Medical Centers

  • Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China

  • Department of Hematology,Fuxing Hospital,Beijing,China

  • Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China

  • Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • B lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Lymphomas

  • B-cell acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Cluster of Differentiation 38

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclosporine eent

  • Methotrexate

  • daratumumab Intravenous

  • Venetoclax

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved